Christine C Ekenga1, Xiaoyan Wang1, Maria Pérez2, Mario Schootman3, Donna B Jeffe2. 1. Brown School, Washington University in St. Louis, St. Louis, Missouri. 2. Department of Medicine, Washington University School of Medicine, St. Louis, Missouri. 3. Department of Clinical Analytics and Insight, Center for Clinical Excellence, SSM Health, St. Louis, Missouri.
Abstract
Background: Weight gain after breast cancer has been associated with recurrence and mortality. We therefore examined factors associated with ≥5% weight gain over 2-year follow-up of a cohort of newly diagnosed early-stage invasive breast cancer (EIBC) and ductal carcinoma in situ (DCIS) patients and age-matched controls without a breast cancer history. Materials and Methods: We interviewed participants 4-6 weeks after definitive surgical treatment (patients) or a negative/benign screening mammogram (controls). Multivariable logistic regression models were used to identify socioeconomic, psychosocial, and treatment factors associated with ≥5% weight gain over 2-year follow-up. Results: Overall, 88 (24%) of 362 EIBC patients, 31 (17%) of 178 DCIS patients, and 82 (15%) of 541 controls had ≥5% weight gain during follow-up. EIBC patients were more likely to experience ≥5% weight gain than DCIS patients (Odds ratio [OR] = 2.16; 95% confidence interval [95% CI] = 1.19-3.95) and controls (OR = 1.76; 95% CI = 1.23-2.51). Among EIBC patients, older patients (OR = 0.96; 95% CI = 0.93-0.99), patients who underwent endocrine therapy (OR = 0.43; 95% CI = 0.19-0.95), smokers (OR = 0.35; 95% CI = 0.14-0.86), and African Americans (OR = 0.23; 95% CI = 0.09-0.58) were less likely to have ≥5% weight gain than their respective counterparts. Among DCIS patients, older patients (OR = 0.94; 95% CI = 0.89-0.99) were less likely to have ≥5% weight gain. Among controls, smokers were more likely to have ≥5% weight gain (OR = 3.03; 95% CI = 1.49-6.17). Conclusions: EIBC patients were more likely than DCIS patients and controls to experience ≥5% weight gain over follow-up. Studies are necessary to elucidate mechanisms of weight gain in early-stage breast cancer survivors.
Background: Weight gain after breast cancer has been associated with recurrence and mortality. We therefore examined factors associated with ≥5% weight gain over 2-year follow-up of a cohort of newly diagnosed early-stage invasive breast cancer (EIBC) and ductal carcinoma in situ (DCIS) patients and age-matched controls without a breast cancer history. Materials and Methods: We interviewed participants 4-6 weeks after definitive surgical treatment (patients) or a negative/benign screening mammogram (controls). Multivariable logistic regression models were used to identify socioeconomic, psychosocial, and treatment factors associated with ≥5% weight gain over 2-year follow-up. Results: Overall, 88 (24%) of 362 EIBCpatients, 31 (17%) of 178 DCIS patients, and 82 (15%) of 541 controls had ≥5% weight gain during follow-up. EIBCpatients were more likely to experience ≥5% weight gain than DCIS patients (Odds ratio [OR] = 2.16; 95% confidence interval [95% CI] = 1.19-3.95) and controls (OR = 1.76; 95% CI = 1.23-2.51). Among EIBCpatients, older patients (OR = 0.96; 95% CI = 0.93-0.99), patients who underwent endocrine therapy (OR = 0.43; 95% CI = 0.19-0.95), smokers (OR = 0.35; 95% CI = 0.14-0.86), and African Americans (OR = 0.23; 95% CI = 0.09-0.58) were less likely to have ≥5% weight gain than their respective counterparts. Among DCIS patients, older patients (OR = 0.94; 95% CI = 0.89-0.99) were less likely to have ≥5% weight gain. Among controls, smokers were more likely to have ≥5% weight gain (OR = 3.03; 95% CI = 1.49-6.17). Conclusions: EIBCpatients were more likely than DCIS patients and controls to experience ≥5% weight gain over follow-up. Studies are necessary to elucidate mechanisms of weight gain in early-stage breast cancer survivors.
Entities:
Keywords:
breast cancer; ductal carcinoma in situ (DCIS); early-stage breast cancer (EIBC); estrogen receptor; weight gain
Authors: Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler Journal: CA Cancer J Clin Date: 2012-04-26 Impact factor: 508.702
Authors: Jiyoung Ahn; Arthur Schatzkin; James V Lacey; Demetrius Albanes; Rachel Ballard-Barbash; Kenneth F Adams; Victor Kipnis; Traci Mouw; Albert R Hollenbeck; Michael F Leitzmann Journal: Arch Intern Med Date: 2007-10-22
Authors: Nazmus Saquib; Shirley W Flatt; Loki Natarajan; Cynthia A Thomson; Wayne A Bardwell; Bette Caan; Cheryl L Rock; John P Pierce Journal: Breast Cancer Res Treat Date: 2006-11-23 Impact factor: 4.872
Authors: Nadia Howlader; Sean F Altekruse; Christopher I Li; Vivien W Chen; Christina A Clarke; Lynn A G Ries; Kathleen A Cronin Journal: J Natl Cancer Inst Date: 2014-04-28 Impact factor: 13.506
Authors: R J Freedman; N Aziz; D Albanes; T Hartman; D Danforth; S Hill; N Sebring; J C Reynolds; J A Yanovski Journal: J Clin Endocrinol Metab Date: 2004-05 Impact factor: 5.958
Authors: Noémie Travier; Antonio Agudo; Anne M May; Carlos Gonzalez; Jian'an Luan; Nick J Wareham; H Bas Bueno-de-Mesquita; Saskia W van den Berg; Nadia Slimani; Sabina Rinaldi; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Domenico Palli; Sabina Sieri; Amalia Mattiello; Rosario Tumino; Paolo Vineis; Teresa Norat; Dora Romaguera; Laudina Rodriguez; Maria-José Sanchez; Miren Dorronsoro; Aurelio Barricarte; José M Huerta; Tim J Key; Philippos Orfanos; Androniki Naska; Antonia Trichopoulou; Sabina Rohrmann; Rudolf Kaaks; Manuela M Bergmann; Heiner Boeing; Goran Hallmans; Ingegerd Johansson; Jonas Manjer; Björn Lindkvist; Mariane U Jakobsen; Kim Overvad; Anne Tjonneland; Jytte Halkjaer; Eiliv Lund; Toni Braaten; Andreani Odysseos; Elio Riboli; Petra H Peeters Journal: Prev Med Date: 2011-09-12 Impact factor: 4.018